The deal represents a 0.33% change in 13F reportable assets under management. LVM's post-trade position is 39,485 shares valued at $19.74 million. NOC shares now account for 2.05% of the fund’s U.S.

Provides clinical development services, including early and late-phase trials, patient recruitment, medical imaging, laboratory services, and regulatory consulting, primarily for the pharmaceutical, ...

Offers advanced aerospace and defense products, including aircraft systems, unmanned autonomous systems, weapons, sensors, cyber solutions, and space systems. Operates through four main segments: ...

Stock price: $147.59 as of July 8, 2025; one-year change: (54%); underperformed S&P 500 by 65.9 percentage points over the past year. No dividend; forward P/E ratio is 11.1; EV/EBITDA (LTM) is 10.1.